By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
For programmes targeting pain and epilepsy, accurate measurement of KV7 ion channel gating behaviour is critical. Metrion assays provide reproducible, high-content data to support confident compound progression.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.